DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA.
The generic ingredient in LICART is diclofenac epolamine. There are forty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the diclofenac epolamine profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LICART
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
ATC Classes for LICART
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Ibsa Inst Bio||LICART||diclofenac epolamine||SYSTEM;TOPICAL||206976-001||Dec 19, 2018||RX||Yes||Yes||Get Started Free||Get Started Free||Get Started Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|